Jeni joined Pivotal in 2019, investing across therapeutics and life sciences with a primary focus in early–stage therapeutics since 2021. Prior to Pivotal, she was at Novo Ventures supporting the firm’s investments across healthcare. Before joining Novo, Jeni interned with the Director of Research at Aquilo Capital Management, a hedge fund focused on smid–cap biotechs. Additionally, Jeni was a co–founder of ViVita Technologies, a cardiovascular–focused preclinical medtech startup. Jeni currently serves on the board of directors of Addition Therapeutics and DermBiont and as an observer for Secure Transfusion Solutions (STS). She previously served as an observer on the board of directors of Rallybio (NASDAQ:RLYB) and Inozyme Pharma (NASDAQ:INZY). Jeni volunteers with the Breaking 7% network to promote women in venture capital and previously volunteered with the New England Venture Network (NEVN). Jeni earned her Ph.D. in Biomedical Engineering with a Designated Emphasis in Biotechnology from the University of California, Davis, and her B.S. in Bioengineering from the University of California, Berkeley.
Partner – Pivotal bioVenture Partners (US)